T-cell large granular lymphocyte leukemia in solid organ transplant recipients: case series and review of the literature
| Autor: | Caterina Cerami, Gianni Cappelli, Mario Luppi, Francesco Fontana, Giacomo Mori, Gaetano Alfano, Elisabetta Colaci, Andrea Messerotti, Leonardo Potenza |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Lymphocytosis Anemia Gastroenterology Post-transplant lymphoproliferative disorder Disease-Free Survival Solid organ transplantation Internal medicine medicine Humans T-Cell Large Granular Lymphocyte Leukemia Hematology business.industry T-cell large granular lymphocyte leukemia T-LGL Cancer Organ Transplantation Middle Aged medicine.disease Transplant Recipients Transplantation Leukemia Large Granular Lymphocytic Survival Rate Leukemia Female medicine.symptom business |
| Zdroj: | International journal of hematology. 110(3) |
| ISSN: | 1865-3774 |
| Popis: | T-cell large granular lymphocyte (T-LGL) leukemia is a rare clonal proliferation of cytotoxic lymphocytes rarely described in solid organ transplant (SOT). We reviewed records from 656 kidney transplant recipients in follow-up at our Center from January 1998 to July 2017. In addition, we researched, through PubMed, further reports of T-LGL leukemia in SOT from March 1981 to December 2017. We identified six cases of T-LGL leukemia in our cohort of patients and 10 in the literature. This lymphoproliferative disorder was detected in one combined liver–kidney, one liver and 14–kidney transplant recipients. Median age at presentation was 46.5 years (IQR 39.2–56.9). The disease developed after a median age of 10 years (IQR 4.9–12) from transplantation. Anemia was the most common presentation (62.5%) followed by lymphocytosis (43.7%) and thrombocytopenia (31.2%). Splenomegaly was reported in 43.7% of the patients. Eight patients (50%) who experienced severe symptoms were treated with non-specific immunosuppressive agents. Six of them (75%) had a good outcome, whereas two (25%) remained red blood cell transfusion dependent. No cases progressed to aggressive T-LGL leukemia or died of cancer at the end of follow-up. These results suggest that T-LGL leukemia is a rare but potentially disruptive hematological disorder in the post-transplant period. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink